Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor
An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which...
Saved in:
Published in | Molecular pharmacology Vol. 103; no. 3; pp. 176 - 187 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.03.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC50 than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor.
Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein–coupled receptors. |
---|---|
AbstractList | An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC
than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor. SIGNIFICANCE STATEMENT: Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein-coupled receptors. An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC50 than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor. SIGNIFICANCE STATEMENT: Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein-coupled receptors.An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC50 than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor. SIGNIFICANCE STATEMENT: Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein-coupled receptors. An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the dopamine D1 receptor. We synthesized the more active enantiomer of Compound A (BMS-A1) and compared it with the D1 PAMs DETQ and MLS6585, which are known to bind to intracellular loop 2 and the extracellular portion of transmembrane helix 7, respectively. Results from D1/D5 chimeras indicated that PAM activity of BMS-A1 tracked with the presence of D1 sequence in the N-terminal/extracellular region of the D1 receptor, a unique location compared with either of the other PAMs. In pairwise combinations, BMS-A1 potentiated the small allo-agonist activity of each of the other PAMs, while the triple PAM combination (in the absence of dopamine) produced a cAMP response about 64% of the maximum produced by dopamine. Each of the pairwise PAM combinations produced a much larger leftward shift of the dopamine EC50 than either single PAM alone. All three PAMs in combination produced a 1000-fold leftward shift of the dopamine curve. These results demonstrate the presence of three non-overlapping allosteric sites that cooperatively stabilize the same activated state of the human D1 receptor. Deficiencies in dopamine D1 receptor activation are seen in Parkinson disease and other neuropsychiatric disorders. In this study, three positive allosteric modulators of the dopamine D1 receptor were found to bind to distinct and separate sites, interacting synergistically with each other and dopamine, with the triple combination causing a 1000-fold leftward shift of the response to dopamine. These results showcase multiple opportunities to modulate D1 tone and highlight new pharmacological approaches for allosteric modulation of G-protein–coupled receptors. |
Author | Willard, Francis S. Bruns, Robert F. Hembre, Erik J. Beck, James P. Svensson, Kjell A. Goldsmith, Paul J. Wang, Xushan |
Author_xml | – sequence: 1 givenname: Xushan surname: Wang fullname: Wang, Xushan – sequence: 2 givenname: Erik J. surname: Hembre fullname: Hembre, Erik J. – sequence: 3 givenname: Paul J. surname: Goldsmith fullname: Goldsmith, Paul J. – sequence: 4 givenname: James P. surname: Beck fullname: Beck, James P. – sequence: 5 givenname: Kjell A. surname: Svensson fullname: Svensson, Kjell A. – sequence: 6 givenname: Francis S. orcidid: 0000-0002-4260-2451 surname: Willard fullname: Willard, Francis S. email: willardfs@lilly.com – sequence: 7 givenname: Robert F. orcidid: 0000-0001-7142-9881 surname: Bruns fullname: Bruns, Robert F. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36804203$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1r3DAQhkVJaDZpf0Gh6NiLtzOSZUuHHsL2M6QU2gRyE4o8ZlVsy5XkQP59XTZ76SGnmcP7vMw85-xkihMx9gZhiyjq92Mc5r1L4xaF2AJAA-oF26ASWAEinrANgGgqbdTdGTvP-TcA1krDS3YmGw21ALlhV9-XsriB72KcKbkSHkJ55LHnN_tExC-HIeZCKXj-KxTKPE687Il_jLMbw7QuyH-Sp7nE9Iqd9m7I9PppXrDbz59udl-r6x9fvu0urysv0ajKKQXGCI1QI3aNkE4okqZtjalb2Uitu_U6aIR2XvXmXna9g7buiRT02qC8YO8OvXOKfxbKxY4hexoGN1FcshVtq00rjBJr9O1TdLkfqbNzCqNLj_b4_xowh4BPMedEvfWhrBbiVJILg0Ww_1zbo2u7urYH1ysr_2OP9c9THw4UrYoeAiWbfaDJUxcS-WK7GJ7l_wK61pdi |
CitedBy_id | crossref_primary_10_1016_j_neuroscience_2024_10_004 crossref_primary_10_3390_ijms241612848 crossref_primary_10_1016_j_rechem_2024_101363 crossref_primary_10_1093_nar_gkad279 |
Cites_doi | 10.3389/fnint.2014.00056 10.1016/j.drudis.2020.12.001 10.1016/j.biopsych.2015.12.028 10.1016/S0026-895X(25)13145-3 10.1002/mds.28879 10.1038/nature12735 10.1096/fasebj.2021.35.S1.02361 10.1038/nature09648 10.1021/acs.jmedchem.1c02169 10.1523/JNEUROSCI.17-21-08580.1997 10.1124/mol.118.112649 10.1021/acs.jmedchem.9b01234 10.2174/1568026619666190712210903 10.1124/mol.118.113175 10.1016/j.vascn.2014.01.002 10.1016/S0022-2836(65)80285-6 10.1016/bs.apha.2019.06.001 10.1016/j.cell.2021.01.028 10.1038/nrd3954 10.1146/annurev.pharmtox.47.120505.105159 10.1038/s41467-022-30929-w 10.1038/s41586-018-0259-z 10.1016/j.neuropharm.2017.10.032 10.1021/acschembio.2c00048 10.1124/jpet.116.236372 10.1016/S0026-895X(25)14327-7 10.1124/pr.110.002642 10.1016/S0026-895X(25)09591-4 10.1021/acs.jmedchem.5b01105 10.1038/s41586-021-03897-2 10.1124/jpet.115.224071 10.1124/pr.54.2.323 10.1177/1087057109357789 10.1038/287651a0 10.1016/j.tips.2016.06.001 10.1073/pnas.95.7.4040 10.1126/science.1215904 10.1038/nrd.2016.230 10.1038/s41422-021-00482-0 |
ContentType | Journal Article |
Copyright | 2023 American Society for Pharmacology and Experimental Therapeutics Copyright © 2023 by The Author(s). |
Copyright_xml | – notice: 2023 American Society for Pharmacology and Experimental Therapeutics – notice: Copyright © 2023 by The Author(s). |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1124/molpharm.122.000605 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-0111 |
EndPage | 187 |
ExternalDocumentID | 36804203 10_1124_molpharm_122_000605 S0026895X24012732 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .55 .GJ 0R~ 123 18M 2WC 34G 39C 4.4 53G 5RE 5VS AAXUO ABCQX ABJNI ABSQV ACGFO ACGFS ADBBV ADCOW AENEX AERNN AFFNX AFOSN ALMA_UNASSIGNED_HOLDINGS AYCSE BAWUL BTFSW CS3 DIK E3Z EBS EJD F5P F9R FDB GX1 H13 HZ~ IH2 INIJC K-O KQ8 L7B LSO M41 MVM N9A O9- OK1 P2P R.V R0Z RHI ROL RPT TR2 UQL W8F WOQ X7M XOL YBU YHG ZGI ZXP AALRI AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c3195-a550992810411d623a25e3977994736388d6800628ac5f9b3dfa074fee50f8913 |
ISSN | 0026-895X 1521-0111 |
IngestDate | Fri Jul 11 08:28:41 EDT 2025 Thu Apr 03 07:05:13 EDT 2025 Thu Apr 24 23:02:29 EDT 2025 Tue Jul 01 05:29:34 EDT 2025 Sun Apr 06 06:54:50 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | GPCR ICL2 NAM CRC PAM ECL |
Language | English |
License | Copyright © 2023 by The Author(s). |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3195-a550992810411d623a25e3977994736388d6800628ac5f9b3dfa074fee50f8913 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-4260-2451 0000-0001-7142-9881 |
OpenAccessLink | https://molpharm.aspetjournals.org/content/molpharm/early/2022/12/09/molpharm.122.000605.full.pdf |
PMID | 36804203 |
PQID | 2778972952 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_2778972952 pubmed_primary_36804203 crossref_citationtrail_10_1124_molpharm_122_000605 crossref_primary_10_1124_molpharm_122_000605 elsevier_sciencedirect_doi_10_1124_molpharm_122_000605 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | March 2023 2023-03-00 20230301 |
PublicationDateYYYYMMDD | 2023-03-01 |
PublicationDate_xml | – month: 03 year: 2023 text: March 2023 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular pharmacology |
PublicationTitleAlternate | Mol Pharmacol |
PublicationYear | 2023 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Kruse, Ring, Manglik, Hu, Hu, Eitel, Hübner, Pardon, Valant, Sexton (bib22) 2013; 504 Nemeth, Steffey, Hammerland, Hung, Van Wagenen, DelMar, Balandrin (bib30) 1998; 95 Bruns, Mitchell, Wafford, Harper, Shanks, Carter, O’Neill, Murray, Eastwood, Schaus (bib7) 2018; 128 Wang, Yu, Xiao, Lu, Zhang (bib40) 2021; 26 Biglan, Munsie, Svensson, Ardayfio, Pugh, Sims, Brys (bib5) 2022; 37 Kenakin, Christopoulos (bib20) 2013; 12 Santos, Ursu, Gaulton, Bento, Donadi, Bologa, Karlsson, Al-Lazikani, Hersey, Oprea (bib32) 2017; 16 Luderman, Free, Koenigsberg, Aubé, Frankowski, Neve, Sibley (bib24) 2021; 35 Christopoulos, Kenakin (bib8) 2002; 54 Ikemoto, Glazier, Murphy, McBride (bib18) 1997; 17 Hany, Leyris, Bret, Mallié, Sar, Thouaye, Hamze, Provot, Sokoloff, Valmier (bib16) 2022; 17 Thal, Glukhova, Sexton, Christopoulos (bib38) 2018; 559 Hao, Beck, Schaus, Krushinski, Chen, Beadle, Vidal, Reinhard, Dressman, Massey (bib17) 2019; 62 Ehlert, Griffin (bib10) 2014; 69 Beadle CD, Coates DA, Hao J, Krushinski JH, Reinhard MR, Schaus JM, Wolfangel CD (2014) 3,4-dihydroisoquinolin-2(1H)-yl compounds. Patent WO 2014/193781 A1, pp 1-90. 2014 Apr 12. Naidu, Patel, McAuliffe, Ding, Cianci, Simmermacher, Jenkins, Parker, Sivaprakasam, Khan (bib28) 2022; 65 Nakamura, Sato, Kitsukawa, Momiyama, Yamamori, Sasaoka (bib29) 2014; 8 Svensson, Heinz, Schaus, Beck, Hao, Krushinski, Reinhard, Cohen, Hellman, Getman (bib36) 2017; 360 Xiao, Yan, Gou, Zhong, Kong, Wu, Wen, Yuan, Cao, Qu (bib41) 2021; 184 Ehlert (bib11) 1988; 33 Alexander, Christopoulos, Davenport, Kelly, Mathie, Peters, Veale, Armstrong, Faccenda, Harding (bib1) 2021; 178 Wang, Heinz, Qian, Carter, Gadski, Beavers, Little, Yang, Beck, Hao (bib39) 2018; 94 Lewis, Hunihan, Watson, Gentles, Hu, Huang, Bronson, Macor, Beno, Ferrante (bib23) 2015; 354 Rasmussen, Choi, Fung, Pardon, Casarosa, Chae, Devree, Rosenbaum, Thian, Kobilka (bib31) 2011; 469 Hanson, Roth, Jo, Griffith, Scott, Reinhart, Desale, Clemons, Cahalan, Schuerer (bib15) 2012; 335 Teng, Chen, Nie, Xiao, Yu, Shao, Zheng (bib37) 2022; 13 Irwin, Duan, Torosyan, Doak, Ziebart, Sterling, Tumanian, Shoichet (bib19) 2015; 58 Beaulieu, Gainetdinov (bib4) 2011; 63 Draper-Joyce, Bhola, Wang, Bhattarai, Nguyen, Cowie-Kent, O’Sullivan, Chia, Venugopal, Valant (bib9) 2021; 597 Luderman, Conroy, Free, Southall, Ferrer, Sanchez-Soto, Moritz, Willette, Fyfe, Jain (bib25) 2018; 94 Shiraki, Tobe, Kawakami, Moritomo, Ohmiya (bib33) 2015 Arnsten, Girgis, Gray, Mailman (bib2) 2017; 81 Svensson, Hao, Bruns (bib35) 2019; 86 Monod, Wyman, Changeux (bib27) 1965; 12 Zhuang, Krumm, Zhang, Zhou, Wang, Huang, Liu, Cheng, Jiang, Jiang (bib42) 2021; 31 Felsing, Jain, Allen (bib13) 2019; 19 Kenakin (bib21) 2010; 15 Bruns, Fergus (bib6) 1990; 38 May, Leach, Sexton, Christopoulos (bib26) 2007; 47 Stockton, Birdsall, Burgen, Hulme (bib34) 1983; 23 Gavish, Snyder (bib14) 1980; 287 Ehlert (bib12) 2016; 37 Teng (10.1124/molpharm.122.000605_bib37) 2022; 13 Felsing (10.1124/molpharm.122.000605_bib13) 2019; 19 Kruse (10.1124/molpharm.122.000605_bib22) 2013; 504 Ehlert (10.1124/molpharm.122.000605_bib12) 2016; 37 10.1124/molpharm.122.000605_bib3 Gavish (10.1124/molpharm.122.000605_bib14) 1980; 287 Ehlert (10.1124/molpharm.122.000605_bib10) 2014; 69 Luderman (10.1124/molpharm.122.000605_bib24) 2021; 35 Svensson (10.1124/molpharm.122.000605_bib36) 2017; 360 Alexander (10.1124/molpharm.122.000605_bib1) 2021; 178 Nemeth (10.1124/molpharm.122.000605_bib30) 1998; 95 Wang (10.1124/molpharm.122.000605_bib39) 2018; 94 Beaulieu (10.1124/molpharm.122.000605_bib4) 2011; 63 Ehlert (10.1124/molpharm.122.000605_bib11) 1988; 33 Luderman (10.1124/molpharm.122.000605_bib25) 2018; 94 Rasmussen (10.1124/molpharm.122.000605_bib31) 2011; 469 Svensson (10.1124/molpharm.122.000605_bib35) 2019; 86 Thal (10.1124/molpharm.122.000605_bib38) 2018; 559 Irwin (10.1124/molpharm.122.000605_bib19) 2015; 58 Hao (10.1124/molpharm.122.000605_bib17) 2019; 62 Kenakin (10.1124/molpharm.122.000605_bib21) 2010; 15 Stockton (10.1124/molpharm.122.000605_bib34) 1983; 23 Kenakin (10.1124/molpharm.122.000605_bib20) 2013; 12 Lewis (10.1124/molpharm.122.000605_bib23) 2015; 354 Ikemoto (10.1124/molpharm.122.000605_bib18) 1997; 17 Bruns (10.1124/molpharm.122.000605_bib7) 2018; 128 Wang (10.1124/molpharm.122.000605_bib40) 2021; 26 Zhuang (10.1124/molpharm.122.000605_bib42) 2021; 31 May (10.1124/molpharm.122.000605_bib26) 2007; 47 Santos (10.1124/molpharm.122.000605_bib32) 2017; 16 Arnsten (10.1124/molpharm.122.000605_bib2) 2017; 81 Christopoulos (10.1124/molpharm.122.000605_bib8) 2002; 54 Hanson (10.1124/molpharm.122.000605_bib15) 2012; 335 Naidu (10.1124/molpharm.122.000605_bib28) 2022; 65 Xiao (10.1124/molpharm.122.000605_bib41) 2021; 184 Monod (10.1124/molpharm.122.000605_bib27) 1965; 12 Biglan (10.1124/molpharm.122.000605_bib5) 2022; 37 Bruns (10.1124/molpharm.122.000605_bib6) 1990; 38 Draper-Joyce (10.1124/molpharm.122.000605_bib9) 2021; 597 Shiraki (10.1124/molpharm.122.000605_bib33) 2015 Hany (10.1124/molpharm.122.000605_bib16) 2022; 17 Nakamura (10.1124/molpharm.122.000605_bib29) 2014; 8 |
References_xml | – volume: 33 start-page: 187 year: 1988 end-page: 194 ident: bib11 article-title: Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods publication-title: Mol Pharmacol – volume: 94 start-page: 1197 year: 2018 end-page: 1209 ident: bib25 article-title: Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites publication-title: Mol Pharmacol – volume: 26 start-page: 690 year: 2021 end-page: 703 ident: bib40 article-title: Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery publication-title: Drug Discov Today – start-page: A1 year: 2015 ident: bib33 article-title: Heterocyclic acetamide compound publication-title: Patent – volume: 38 start-page: 939 year: 1990 end-page: 949 ident: bib6 article-title: Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes publication-title: Mol Pharmacol – volume: 178 start-page: S27 year: 2021 end-page: S156 ident: bib1 article-title: THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors publication-title: Br J Pharmacol – volume: 81 start-page: 67 year: 2017 end-page: 77 ident: bib2 article-title: Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia publication-title: Biol Psychiatry – volume: 86 start-page: 273 year: 2019 end-page: 305 ident: bib35 article-title: Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders publication-title: Adv Pharmacol – volume: 559 start-page: 45 year: 2018 end-page: 53 ident: bib38 article-title: Structural insights into G-protein-coupled receptor allostery publication-title: Nature – volume: 597 start-page: 571 year: 2021 end-page: 576 ident: bib9 article-title: Positive allosteric mechanisms of adenosine A publication-title: Nature – volume: 69 start-page: 253 year: 2014 end-page: 279 ident: bib10 article-title: Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias publication-title: J Pharmacol Toxicol Methods – volume: 16 start-page: 19 year: 2017 end-page: 34 ident: bib32 article-title: A comprehensive map of molecular drug targets publication-title: Nat Rev Drug Discov – volume: 62 start-page: 8711 year: 2019 end-page: 8732 ident: bib17 article-title: Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1 publication-title: J Med Chem – volume: 23 start-page: 551 year: 1983 end-page: 557 ident: bib34 article-title: Modification of the binding properties of muscarinic receptors by gallamine publication-title: Mol Pharmacol – volume: 37 start-page: 620 year: 2016 end-page: 623 ident: bib12 article-title: Cooperativity Has Empirical and Ultimate Levels of Explanation publication-title: Trends Pharmacol Sci – volume: 17 start-page: 8580 year: 1997 end-page: 8587 ident: bib18 article-title: Role of dopamine D1 and D2 receptors in the nucleus accumbens in mediating reward publication-title: J Neurosci – volume: 63 start-page: 182 year: 2011 end-page: 217 ident: bib4 article-title: The physiology, signaling, and pharmacology of dopamine receptors publication-title: Pharmacol Rev – volume: 12 start-page: 88 year: 1965 end-page: 118 ident: bib27 article-title: On the nature of allosteric transitions: a plausible model publication-title: J Mol Biol – volume: 12 start-page: 205 year: 2013 end-page: 216 ident: bib20 article-title: Signalling bias in new drug discovery: detection, quantification and therapeutic impact publication-title: Nat Rev Drug Discov – volume: 31 start-page: 593 year: 2021 end-page: 596 ident: bib42 article-title: Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor publication-title: Cell Res – reference: Beadle CD, Coates DA, Hao J, Krushinski JH, Reinhard MR, Schaus JM, Wolfangel CD (2014) 3,4-dihydroisoquinolin-2(1H)-yl compounds. Patent WO 2014/193781 A1, pp 1-90. 2014 Apr 12. – volume: 15 start-page: 119 year: 2010 end-page: 130 ident: bib21 article-title: Ligand detection in the allosteric world publication-title: J Biomol Screen – volume: 354 start-page: 340 year: 2015 end-page: 349 ident: bib23 article-title: Discovery of D1 dopamine receptor positive allosteric modulators: characterization of pharmacology and identification of residues that regulate species selectivity publication-title: J Pharmacol Exp Ther – volume: 19 start-page: 1365 year: 2019 end-page: 1380 ident: bib13 article-title: Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics publication-title: Curr Top Med Chem – volume: 54 start-page: 323 year: 2002 end-page: 374 ident: bib8 article-title: G protein-coupled receptor allosterism and complexing publication-title: Pharmacol Rev – volume: 469 start-page: 175 year: 2011 end-page: 180 ident: bib31 article-title: Structure of a nanobody-stabilized active state of the β(2) adrenoceptor publication-title: Nature – volume: 8 start-page: 56 year: 2014 ident: bib29 article-title: Distinct motor impairments of dopamine D1 and D2 receptor knockout mice revealed by three types of motor behavior publication-title: Front Integr Nuerosci – volume: 335 start-page: 851 year: 2012 end-page: 855 ident: bib15 article-title: Crystal structure of a lipid G protein-coupled receptor publication-title: Science – volume: 504 start-page: 101 year: 2013 end-page: 106 ident: bib22 article-title: Activation and allosteric modulation of a muscarinic acetylcholine receptor publication-title: Nature – volume: 94 start-page: 1232 year: 2018 end-page: 1245 ident: bib39 article-title: Intracellular binding site for a positive allosteric modulator of the dopamine D1 receptor publication-title: Mol Pharmacol – volume: 37 start-page: 513 year: 2022 end-page: 524 ident: bib5 article-title: Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial publication-title: Mov Disord – volume: 287 start-page: 651 year: 1980 end-page: 652 ident: bib14 article-title: Benzodiazepine recognition sites on GABA receptors publication-title: Nature – volume: 58 start-page: 7076 year: 2015 end-page: 7087 ident: bib19 article-title: An Aggregation Advisor for Ligand Discovery publication-title: J Med Chem – volume: 47 start-page: 1 year: 2007 end-page: 51 ident: bib26 article-title: Allosteric modulation of G protein-coupled receptors publication-title: Annu Rev Pharmacol Toxicol – volume: 128 start-page: 351 year: 2018 end-page: 365 ident: bib7 article-title: Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders publication-title: Neuropharmacology – volume: 17 start-page: 709 year: 2022 end-page: 722 ident: bib16 article-title: High-Throughput Screening for Extracellular Inhibitors of the FLT3 Receptor Tyrosine Kinase Reveals Chemically Diverse and Druggable Negative Allosteric Modulators publication-title: ACS Chem Biol – volume: 35 start-page: 2361 year: 2021 ident: bib24 article-title: Characterization of a D1 Dopamine Receptor Positive Allosteric Modulator with a Novel Binding Site (Abstract) publication-title: FASEB J – volume: 13 start-page: 3186 year: 2022 ident: bib37 article-title: Ligand recognition and biased agonism of the D1 dopamine receptor publication-title: Nat Commun – volume: 360 start-page: 117 year: 2017 end-page: 128 ident: bib36 article-title: An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis publication-title: J Pharmacol Exp Ther – volume: 95 start-page: 4040 year: 1998 end-page: 4045 ident: bib30 article-title: Calcimimetics with potent and selective activity on the parathyroid calcium receptor publication-title: Proc Natl Acad Sci USA – volume: 65 start-page: 4949 year: 2022 end-page: 4971 ident: bib28 article-title: Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs publication-title: J Med Chem – volume: 184 start-page: 943 year: 2021 end-page: 956.e18 ident: bib41 article-title: Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes publication-title: Cell – volume: 8 start-page: 56 year: 2014 ident: 10.1124/molpharm.122.000605_bib29 article-title: Distinct motor impairments of dopamine D1 and D2 receptor knockout mice revealed by three types of motor behavior publication-title: Front Integr Nuerosci doi: 10.3389/fnint.2014.00056 – volume: 26 start-page: 690 year: 2021 ident: 10.1124/molpharm.122.000605_bib40 article-title: Allosteric binding sites at the receptor-lipid bilayer interface: novel targets for GPCR drug discovery publication-title: Drug Discov Today doi: 10.1016/j.drudis.2020.12.001 – volume: 81 start-page: 67 year: 2017 ident: 10.1124/molpharm.122.000605_bib2 article-title: Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia publication-title: Biol Psychiatry doi: 10.1016/j.biopsych.2015.12.028 – volume: 33 start-page: 187 year: 1988 ident: 10.1124/molpharm.122.000605_bib11 article-title: Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods publication-title: Mol Pharmacol doi: 10.1016/S0026-895X(25)13145-3 – volume: 37 start-page: 513 year: 2022 ident: 10.1124/molpharm.122.000605_bib5 article-title: Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo-Controlled Trial publication-title: Mov Disord doi: 10.1002/mds.28879 – volume: 504 start-page: 101 year: 2013 ident: 10.1124/molpharm.122.000605_bib22 article-title: Activation and allosteric modulation of a muscarinic acetylcholine receptor publication-title: Nature doi: 10.1038/nature12735 – volume: 35 start-page: 2361 issue: S1 year: 2021 ident: 10.1124/molpharm.122.000605_bib24 article-title: Characterization of a D1 Dopamine Receptor Positive Allosteric Modulator with a Novel Binding Site (Abstract) publication-title: FASEB J doi: 10.1096/fasebj.2021.35.S1.02361 – volume: 469 start-page: 175 year: 2011 ident: 10.1124/molpharm.122.000605_bib31 article-title: Structure of a nanobody-stabilized active state of the β(2) adrenoceptor publication-title: Nature doi: 10.1038/nature09648 – volume: 65 start-page: 4949 year: 2022 ident: 10.1124/molpharm.122.000605_bib28 article-title: Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs publication-title: J Med Chem doi: 10.1021/acs.jmedchem.1c02169 – start-page: A1 issue: Number: US20150045402 year: 2015 ident: 10.1124/molpharm.122.000605_bib33 article-title: Heterocyclic acetamide compound publication-title: Patent – volume: 17 start-page: 8580 year: 1997 ident: 10.1124/molpharm.122.000605_bib18 article-title: Role of dopamine D1 and D2 receptors in the nucleus accumbens in mediating reward publication-title: J Neurosci doi: 10.1523/JNEUROSCI.17-21-08580.1997 – volume: 94 start-page: 1232 year: 2018 ident: 10.1124/molpharm.122.000605_bib39 article-title: Intracellular binding site for a positive allosteric modulator of the dopamine D1 receptor publication-title: Mol Pharmacol doi: 10.1124/mol.118.112649 – volume: 62 start-page: 8711 year: 2019 ident: 10.1124/molpharm.122.000605_bib17 publication-title: J Med Chem doi: 10.1021/acs.jmedchem.9b01234 – volume: 19 start-page: 1365 year: 2019 ident: 10.1124/molpharm.122.000605_bib13 article-title: Advances in Dopamine D1 Receptor Ligands for Neurotherapeutics publication-title: Curr Top Med Chem doi: 10.2174/1568026619666190712210903 – volume: 94 start-page: 1197 year: 2018 ident: 10.1124/molpharm.122.000605_bib25 article-title: Identification of positive allosteric modulators of the D1 dopamine receptor that act at diverse binding sites publication-title: Mol Pharmacol doi: 10.1124/mol.118.113175 – volume: 69 start-page: 253 year: 2014 ident: 10.1124/molpharm.122.000605_bib10 article-title: Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias publication-title: J Pharmacol Toxicol Methods doi: 10.1016/j.vascn.2014.01.002 – volume: 12 start-page: 88 year: 1965 ident: 10.1124/molpharm.122.000605_bib27 article-title: On the nature of allosteric transitions: a plausible model publication-title: J Mol Biol doi: 10.1016/S0022-2836(65)80285-6 – volume: 86 start-page: 273 year: 2019 ident: 10.1124/molpharm.122.000605_bib35 article-title: Positive allosteric modulators of the dopamine D1 receptor: A new mechanism for the treatment of neuropsychiatric disorders publication-title: Adv Pharmacol doi: 10.1016/bs.apha.2019.06.001 – volume: 184 start-page: 943 year: 2021 ident: 10.1124/molpharm.122.000605_bib41 article-title: Ligand recognition and allosteric regulation of DRD1-Gs signaling complexes publication-title: Cell doi: 10.1016/j.cell.2021.01.028 – volume: 12 start-page: 205 year: 2013 ident: 10.1124/molpharm.122.000605_bib20 article-title: Signalling bias in new drug discovery: detection, quantification and therapeutic impact publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3954 – volume: 47 start-page: 1 year: 2007 ident: 10.1124/molpharm.122.000605_bib26 article-title: Allosteric modulation of G protein-coupled receptors publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev.pharmtox.47.120505.105159 – volume: 13 start-page: 3186 year: 2022 ident: 10.1124/molpharm.122.000605_bib37 article-title: Ligand recognition and biased agonism of the D1 dopamine receptor publication-title: Nat Commun doi: 10.1038/s41467-022-30929-w – volume: 559 start-page: 45 year: 2018 ident: 10.1124/molpharm.122.000605_bib38 article-title: Structural insights into G-protein-coupled receptor allostery publication-title: Nature doi: 10.1038/s41586-018-0259-z – volume: 128 start-page: 351 year: 2018 ident: 10.1124/molpharm.122.000605_bib7 article-title: Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2017.10.032 – volume: 17 start-page: 709 year: 2022 ident: 10.1124/molpharm.122.000605_bib16 article-title: High-Throughput Screening for Extracellular Inhibitors of the FLT3 Receptor Tyrosine Kinase Reveals Chemically Diverse and Druggable Negative Allosteric Modulators publication-title: ACS Chem Biol doi: 10.1021/acschembio.2c00048 – volume: 360 start-page: 117 year: 2017 ident: 10.1124/molpharm.122.000605_bib36 article-title: An allosteric potentiator of the dopamine D1 receptor increases locomotor activity in human D1 knock-in mice without causing stereotypy or tachyphylaxis publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.116.236372 – volume: 23 start-page: 551 year: 1983 ident: 10.1124/molpharm.122.000605_bib34 article-title: Modification of the binding properties of muscarinic receptors by gallamine publication-title: Mol Pharmacol doi: 10.1016/S0026-895X(25)14327-7 – volume: 63 start-page: 182 year: 2011 ident: 10.1124/molpharm.122.000605_bib4 article-title: The physiology, signaling, and pharmacology of dopamine receptors publication-title: Pharmacol Rev doi: 10.1124/pr.110.002642 – volume: 38 start-page: 939 year: 1990 ident: 10.1124/molpharm.122.000605_bib6 article-title: Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes publication-title: Mol Pharmacol doi: 10.1016/S0026-895X(25)09591-4 – volume: 58 start-page: 7076 year: 2015 ident: 10.1124/molpharm.122.000605_bib19 article-title: An Aggregation Advisor for Ligand Discovery publication-title: J Med Chem doi: 10.1021/acs.jmedchem.5b01105 – volume: 597 start-page: 571 year: 2021 ident: 10.1124/molpharm.122.000605_bib9 article-title: Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia publication-title: Nature doi: 10.1038/s41586-021-03897-2 – volume: 354 start-page: 340 year: 2015 ident: 10.1124/molpharm.122.000605_bib23 article-title: Discovery of D1 dopamine receptor positive allosteric modulators: characterization of pharmacology and identification of residues that regulate species selectivity publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.115.224071 – volume: 178 start-page: S27 issue: Suppl 1 year: 2021 ident: 10.1124/molpharm.122.000605_bib1 article-title: THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors publication-title: Br J Pharmacol – volume: 54 start-page: 323 year: 2002 ident: 10.1124/molpharm.122.000605_bib8 article-title: G protein-coupled receptor allosterism and complexing publication-title: Pharmacol Rev doi: 10.1124/pr.54.2.323 – volume: 15 start-page: 119 year: 2010 ident: 10.1124/molpharm.122.000605_bib21 article-title: Ligand detection in the allosteric world publication-title: J Biomol Screen doi: 10.1177/1087057109357789 – ident: 10.1124/molpharm.122.000605_bib3 – volume: 287 start-page: 651 year: 1980 ident: 10.1124/molpharm.122.000605_bib14 article-title: Benzodiazepine recognition sites on GABA receptors publication-title: Nature doi: 10.1038/287651a0 – volume: 37 start-page: 620 year: 2016 ident: 10.1124/molpharm.122.000605_bib12 article-title: Cooperativity Has Empirical and Ultimate Levels of Explanation publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2016.06.001 – volume: 95 start-page: 4040 year: 1998 ident: 10.1124/molpharm.122.000605_bib30 article-title: Calcimimetics with potent and selective activity on the parathyroid calcium receptor publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.95.7.4040 – volume: 335 start-page: 851 year: 2012 ident: 10.1124/molpharm.122.000605_bib15 article-title: Crystal structure of a lipid G protein-coupled receptor publication-title: Science doi: 10.1126/science.1215904 – volume: 16 start-page: 19 year: 2017 ident: 10.1124/molpharm.122.000605_bib32 article-title: A comprehensive map of molecular drug targets publication-title: Nat Rev Drug Discov doi: 10.1038/nrd.2016.230 – volume: 31 start-page: 593 year: 2021 ident: 10.1124/molpharm.122.000605_bib42 article-title: Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor publication-title: Cell Res doi: 10.1038/s41422-021-00482-0 |
SSID | ssj0014580 |
Score | 2.4312174 |
Snippet | An amine-containing molecule called Compound A has been reported by a group from Bristol-Myers Squibb to act as a positive allosteric modulator (PAM) at the... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 176 |
SubjectTerms | Allosteric Regulation - physiology Allosteric Site - physiology Dopamine - metabolism Humans Receptors, Dopamine D1 - metabolism Receptors, G-Protein-Coupled |
Title | Mutual Cooperativity of Three Allosteric Sites on the Dopamine D1 Receptor |
URI | https://dx.doi.org/10.1124/molpharm.122.000605 https://www.ncbi.nlm.nih.gov/pubmed/36804203 https://www.proquest.com/docview/2778972952 |
Volume | 103 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKeOEFcadsICOhvawdjROn8ePYhbIbk0ilvlmO42iINInW5gF-Pcd2nATRTYOXqHLrJvX3-fSc43NB6INkifCk8sYKGDQOIgl7LqNkLP0ojWBvpcoGyF6Gs3lwuqCLweCsF7VUr5N9-WtjXsn_oApjgKvOkv0HZNsvhQF4DfjCFRCG670wvqhN9sdhWVbqxvWBAO0vBoDU3kGe6wwOHSr_7bt2r9pzAdCZK7HUyuWRp7VGVdmCw62OeuE65u5VXV3rnufdSodFvbrumDVTy8R6s0Gw_ujOmj6XebpqnTeizru3PikriU2cbpNm1rgfiN_FXzmJSbQ_opGYasOYE7MTv8cnvyc0PdsB5m9hTgJAYFnm5tfue8TUVg0ntPvvcuf1l1_5yfz8nMfHi_gBekjAZjD29Zez9kgpoKaNXvtsTQkquMnHDbe4TU25zQwx6kj8BD1u7Ah8YEnxFA1U8QztXlnAfo5w3OXVrUZ4F1_1oHyOTi1z8B_MwWWGDXNwxxxsmIPLAgNzsGMOPvKwY84LND85jg9n46arBuw_3ZhTgE3KGInADoetCNqvIFRpM4CxYOqDOI7SMDKptULSjCV-mgnQMzOl6CTTh9ov0VZRFuo1wjpQkU09KlSSBmEgRSjINFSSkUzRaSKHiLhF5LIpOa87n-TcmJ4k4G7lOaw8tys_RKN2UmUrrtz98dChwxul0SqDHGh098T3DksOIlWfk4lClfWKA3siBkYnJUP0yoLcPokPaxOQif_mHrO30aNux-ygrfVNrd6CCrtO3hlq_ga4nptn |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mutual+Cooperativity+of+Three+Allosteric+Sites+on+the+Dopamine+D1+Receptor&rft.jtitle=Molecular+pharmacology&rft.au=Wang%2C+Xushan&rft.au=Hembre%2C+Erik+J&rft.au=Goldsmith%2C+Paul+J&rft.au=Beck%2C+James+P&rft.date=2023-03-01&rft.issn=1521-0111&rft.eissn=1521-0111&rft.volume=103&rft.issue=3&rft.spage=176&rft_id=info:doi/10.1124%2Fmolpharm.122.000605&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0026-895X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0026-895X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0026-895X&client=summon |